Corvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock Up [Yahoo! Finance]
Corvus Pharmaceuticals, Inc. (CRVS)
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corvuspharma.com
Company Research
Source: Yahoo! Finance
The FDA generally grants this designation to investigational therapies that address rare medical diseases or conditions affecting fewer than 200,000 people in the United States. The perquisites that come from this designation include assistance in the drug development process, tax credits for clinical costs, exemptions from certain FDA fees and seven years of post-approval marketing exclusivity. The company's shares rose 10.75% on the news. Soquelitinib (formerly known as CPI-818) is an investigational small molecule drug given orally, designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer cell immune function. The company is on track to advance the candidate into a phase III registrational clinical study in patients with relapsed peripheral T cell lymphoma (PTCL) in the second quarter of 2024. In December, CRVS reported new interim data from its phase I/Ib c
Show less
Read more
Impact Snapshot
Event Time:
CRVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRVS alerts
High impacting Corvus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRVS
News
- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $7.00 to $8.00. They now have an "outperform" rating on the stock.MarketBeat
- Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsGlobeNewswire
- Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024 [Yahoo! Finance]Yahoo! Finance
- Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024GlobeNewswire
CRVS
Earnings
- 5/6/24 - In-Line
CRVS
Sec Filings
- 5/6/24 - Form 8-K
- 5/6/24 - Form 8-K
- 5/3/24 - Form 424B5
- CRVS's page on the SEC website